The IND application for TQF3250 Capsules, a Class 1 innovative drug from China Biopharmaceuticals, with hypoglycemic activity comparable to similar drugs, has been accepted by the National Medical Products Administration (NMPA).
September 23, 2025
Source: drugdu
128
On September 22, China Biopharmaceutical (01177) announced that the company's independently developed national Class 1 innovative drugThe new drug clinical trial application (IND) for TQF3250 capsules, a "GLP-1 receptor agonist", has been accepted by the China National Medical Products Administration (NMPA) and is intended for the treatment of type 2 diabetes.
TQF3250 is an oral, small-molecule, preferential GLP-1RA that selectively activates the cAMP-preferred GLP-1R signaling pathway, effectively promoting insulin secretion. Preclinical studies have shown that in mouse models, TQF3250 significantly improves glucose tolerance at doses as low as 1 mg/kg, demonstrating comparable activity to the similar drug orforglipron, demonstrating a highly effective hypoglycemic effect.
Furthermore, TQF3250 has a no-adverse-effect-level (NOAEL) of 24 mg/kg/day, and no significant cardiotoxicity or genotoxicity risk has been observed, demonstrating a favorable safety profile. The global GLP-1RA market is projected to exceed US$50 billion in 2024 and exceed US$150 billion in 2031. The Company will accelerate the clinical development of TQF3250.
https://finance.eastmoney.com/a/202509223519925098.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Multiple batches of quadrivalent influenza virus split vaccine have been sub-packaged and submitted for lot release approval; expected to be released to the market soon after approval December 12, 2025
- Ab&B Bio-Tech CO., LTD. JS Lyophilized Human Rabies Vaccine Initiates Phase III Clinical Trials December 12, 2025
- The ‘Sweetest’ HPV Vaccine Market is Gone | Haibin Interview December 12, 2025
- InnoCare Pharma announced that its first independently developed next-generation TRK inhibitor, zoletrazinib, has been approved for marketing in China December 12, 2025
- Is PD-1/VEGF dual antibody + ADC becoming the standard configuration? December 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
